Category view
Be the first to catch the latest stories from this category.
Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.
Scientists discovered that damaged fat cells can become inflamed, lose their ability to store lipids, and eventually vanish, disrupting the body’s metabolism. The findings show that diabetes can result not only from excess fat, but also from losing the healthy fat tissue the body needs.
These specialized units can help keep older patients out of the hospital, lower their health care costs and more.
The voluntary recall included eggs produced in Texas and sold under several brand names in six states, the Food and Drug Administration said.
The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.
The agency is considering whether compounding pharmacies should be allowed to produce BPC-157, TB-500 and other previously banned peptides.
“Consumers should not be faced with a trade-off between nutrition and food safety,” writes Susan Mayne, former director of the FDA Center for Food Safety and Applied Nutrition.
Robert F. Kennedy Jr. has lauded peptides and said he takes them himself.
The number of measles cases in the U.S. has surpassed the record-breaking tally for all of 2025, with five more months of 2026 still to come.
From new hires to departures, promotions, and hires, here are the latest comings and goings in the pharma industry.
The Agency for Healthcare Research and Quality slowed the awarding of new grants last year. Now it is stopping existing ones.
Sanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The Readout
A sulfur-based compound called LASSS appears to protect and supercharge a key protein involved in repairing damaged muscle. The discovery could eventually lead to new ways to slow muscle loss and preserve strength as people age.
In a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugs
An experimental pill prevented a measles-like virus from spreading through the air or through close contact in ferrets. It worked when given shortly before or after exposure and also shortened illness and the period when infected animals remained contagious. Researchers say the drug could one day complement vaccination and make outbreaks easier to contain.
A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started quickly.
The national security framing of the discussion around pharmaceutical supply chain vulnerabilities is a distraction, writes Pooja Yerramilli.
The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.
Unexpected alliances among Republicans and Democrats were on display over a bill meant to rein in ultra-processed foods.
A federal loan program made it possible for Gauri Gurumurthy to pursue medicine. Now that program is changing.
The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
Federal health officials are investigating a new outbreak involving the diarrhea-causing parasite cyclospora.
The European Medicines Agency is taking what advocacy groups are calling unexpectedly “rapid action” to ensure that clinical trial results are made public as required by law.
The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
Too few senators were in attendance to proceed with a vote on the CDC director nominee.
Congress is scrambling to advance a slew of health care bills before an August recess. Price transparency and prior authorization top the list.
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare disease? Find out on this week's episode of…
Sean Kaufman, nominated to run ASPR, has a track record of questioning the safety of vaccines.
Timothy Westlake, an emergency doctor nominated to head SAMHSA, has been active in addiction policy in Wisconsin.
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
In this edition of STAT Health Tech: HHS is inviting experts to shape policy on clinical AI, Whoop's new CMO, news about brain implants, and more.
A leading advocacy group petitioned the FDA to ban direct-to-consumer advertising of prescription medicines.
A 25-year study found that frequent consumption of soda, sports drinks, and fruit juice beginning in childhood was linked to a higher risk of high blood pressure in adulthood. Swapping one daily drink for whole fruit, milk, or water could significantly reduce that risk.
The service members who refused the Covid vaccine, the fastest-growing Ebola outbreak in history, and other health news from Morning Rounds
On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
Mirroring the bipartisan bill introduced in the House, the measure would require a study from the GAO on the state of men’s health in the U.S. to be presented within…
New maternal billing codes should create a transparent system where both patients and clinicians can thrive, ACOG writes.
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.
Try another keyword or clear the search box.
